Enasidenib fails to meet primary endpoint in acute myeloid leukaemia trial
In the IDHENTIFY trial, enasidenib, an allosteric inhibitor of mutated IDH2 proteins, failed to improve overall survival in relapsed or refractory acute myeloid leukaemia with an isocitrate dehydrogenase-2 mutation vs conventional care.
Source:
Biospace Inc.
SPS commentary:
Enasidenib is currently licensed in the US for this indication. Manufacturers withdrew the market authorisation application for use in the EU in December 2019 following the EMA’s initial assessment and questions.